A novel targeting modality for renal cell carcinoma: human osteocalcin promoter‐mediated gene therapy synergistically induced by vitamin C and vitamin D3
- 23 November 2010
- journal article
- research article
- Published by Wiley in The Journal of Gene Medicine
- Vol. 12 (11) , 892-903
Abstract
Background: Advanced renal cell carcinoma (RCC) frequently develops skeletal metastasis and is highly resistant to conventional therapies. We hypothesized that the osteocalcin (OC) promoter may be a promising gene delivery system for RCC targeted gene therapy because osteotropic tumors gain osteomimetic properties and thrive in the new environment by exhibiting a bone‐like gene expression profile. Human OC (hOC) expression is highly regulated by vitamins and hormone. In the present study, we tested the feasibility of vitamin‐regulatable hOC promoter for RCC‐specific transcriptional targeting, and examined the anti‐tumor effect of vitamins C and D3with hOC‐based adenoviral vectors towards RCC.Methods: Real‐time reverse transcriptase‐polymerase chain reaction measured OC expression induced by vitamins C and D3, either alone or in combination, in RCC and normal human renal epithelial cells (HRE). The RCC‐cytotoxic effects of concomitant vitamins and hOC promoter‐based adenoviral vectors, Ad‐hOC‐TK and Ad‐hOC‐E1, were evaluated in both cell culture and a xenograft murine model.Results: We found that high doses of vitamin C induced H2O2‐dependent apoptosis in RCC but not HRE. Treatment of RCC cells with combined vitamins C and D3treatment significantly increased OC promoter activity compared to single reagent treatment. Combined vitamin therapy reduced tumor size (85%) and complete tumor regression occurred in 38% of mice co‐administrated Ad‐hOC‐E1.Conclusions: The results obtained in the present study demonstrate that vitamins C and D3synergized with the anti‐tumor effects of therapeutic genes driven by hOC promoter through direct cytotoxicity as well as transcriptional targeting. This combined gene therapy provides a promising modality for advanced RCC targeted therapy. Copyright © 2010 John Wiley & Sons, Ltd.Keywords
This publication has 59 references indexed in Scilit:
- Mechanisms of Ascorbate-Induced Cytotoxicity in Pancreatic CancerClinical Cancer Research, 2010
- Analysis of SNPs and Haplotypes in Vitamin D Pathway Genes and Renal Cancer RiskPLOS ONE, 2009
- Anti-angiogenic effect of high doses of ascorbic acidJournal of Translational Medicine, 2008
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trialThe Lancet, 2008
- Vitamin D Receptor Polymorphisms and Renal Cancer Risk in Central and Eastern EuropeJournal of Toxicology and Environmental Health, Part A, 2008
- Sorafenib in Advanced Clear-Cell Renal-Cell CarcinomaNew England Journal of Medicine, 2007
- Sodium Ascorbate induces apoptosis in neuroblastoma cell lines by interfering with iron uptakeMolecular Cancer, 2007
- Sodium ascorbate inhibits growth via the induction of cell cycle arrest and apoptosis in human malignant melanoma A375.S2 cellsMelanoma Research, 2006
- Sodium ascorbate (vitamin C) induces apoptosis in melanoma cells via the down‐regulation of transferrin receptor dependent iron uptakeJournal of Cellular Physiology, 2005
- Effects of ascorbic acid on collagen matrix formation and osteoblast differentiation in murine MC3T3-E1 cellsJournal of Bone and Mineral Research, 1994